Collaboration with institutions has been pivotal to both new product development and furthering our understanding of the complex protective mechanisms of cooling. Our work in developing and delivering new cryotherapy solutions would not be possible without our valuable research partnerships.

Paxman currently has a Knowledge Transfer Partnership (KTP) with the University of Leeds, where we have just recently recruited an associate who will work with both Paxman and the university and to explore potential developments in the Internet of Things (IoT). The Associate will work closely with our own Product Design Researcher, Dipo Olaosun, and with Dr. Omar Cardosa from Leeds University.

Paxman are also engaging in project collaboration on a wearable CIPN device which is currently in the feasibility stage.

Working with Professor Nik Georgopoulos and his team, Paxman aims to better understand the thermoregulatory and biological response to cooling for the prevention of chemotherapy-induced peripheral neuropathy (CIPN).

Outputs from this work will help inform Paxman of the mechanisms of protection from neuropathy, which can be an extremely debilitating side effect for chemotherapy patients.

In partnership with Kings College, we are exploring the benefits of cooling to prevent Non-Alcoholic Fatty Liver Disease, which can develop into Cirrhosis.

Paxman have provided expert knowledge in cooling as well as wearable heat exchangers to facilitate experimental tests to investigate the development of Brown Adipose Tissue, which is a measure of the positive effect of cooling.

Testing on volunteers takes place in early 2025.

Paxman has a longstanding partnership with Singapore and in 2019 we developed the first portable CIPN cooling device prototype. Clinical trials began in Singapore in 2021 and continue to show very positive outcomes for patients.

The alpha prototype developed in Singapore was improved further into the beta type which is currently being used in U.S. trials, again with very positive outcomes.

We have both a research agreement with NUS and licensing agreement. The CIPN product has been jointly developed and funded with the NUS

The UK’s innovation agency, Innovate UK, aims to help companies grow through their development and commercialisation of new products, processes and services. We continue to build on our strong relationships with the government agency and their advisors who assist Paxman in securing funding to support these very important initiatives.